AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Lonza Group AG
Video analysis: LZAGY
All videosNo video analysis for this stock yet. Request one from our team.
News: LZAGY
Lonza: Strong H1 Execution, Higher Guidance Means Higher Upside
H1 results showed 16% sales growth, a 44% net profit increase, and EBITDA margin expansion to 34.8%, driven by higher asset utilization and segment outperformance. Integrated Biologics, Advanced Synthesis, and Specialized Modalities each delivered double-digit growth. Management raised its 2026 CORE EBITDA margin outlook to 33–34% while maintaining 11–12% sales growth guidance. Our buy rating is confirmed.
Lonza Group AG (LZAGY) Q2 2026 Earnings Call Transcript
Lonza Group AG (LZAGY) Q2 2026 Earnings Call Transcript
PAHC or LZAGY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Lonza Group Ag (LZAGY). But which of these two stocks is more attractive to value investors?